Advertisement

Research Article Free access | 10.1172/JCI118121

Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone.

J Pfeilschifter, F Laukhuf, B Müller-Beckmann, W F Blum, T Pfister, and R Ziegler

University of Heidelberg, Department of Internal Medicine, Germany.

Find articles by Pfeilschifter, J. in: PubMed | Google Scholar

University of Heidelberg, Department of Internal Medicine, Germany.

Find articles by Laukhuf, F. in: PubMed | Google Scholar

University of Heidelberg, Department of Internal Medicine, Germany.

Find articles by Müller-Beckmann, B. in: PubMed | Google Scholar

University of Heidelberg, Department of Internal Medicine, Germany.

Find articles by Blum, W. in: PubMed | Google Scholar

University of Heidelberg, Department of Internal Medicine, Germany.

Find articles by Pfister, T. in: PubMed | Google Scholar

University of Heidelberg, Department of Internal Medicine, Germany.

Find articles by Ziegler, R. in: PubMed | Google Scholar

Published August 1, 1995 - More info

Published in Volume 96, Issue 2 on August 1, 1995
J Clin Invest. 1995;96(2):767–774. https://doi.org/10.1172/JCI118121.
© 1995 The American Society for Clinical Investigation
Published August 1, 1995 - Version history
View PDF
Abstract

Intermittent treatment with parathyroid hormone (PTH) increases bone mass in experimental animals and humans. In vitro studies have suggested that the anabolic effect of PTH may be mediated by local growth factors. However, the relevance of these findings to in vivo situations remains unclear. In this study, we examined a time course of daily s.c. injections of hPTH (1-34) on the skeletal concentration of insulin-like growth factor (IGF)-I, IGF-II, and transforming growth factor beta (TGF-beta) in the proximal tail vertebrae of male rats. PTH caused a time and dose-dependent increase in the bone mineral density of the lumbar spine. This anabolic effect on bone mass was accompanied by progressive increases in bone matrix-associated IGF-I and TGF-beta 1. Increases in IGF-I and TGF-beta 1 became apparent after four and eight weeks of PTH treatment respectively and persisted through week 12. PTH had no effect on circulating IGF-I, suggesting that the increase of bone matrix IGF-I was due to the local effect of PTH on bone tissue directly rather than to an increase of circulating IGF-I. These data are consistent with the hypothesis that IGF-I and TGF-beta 1 may play a role as local mediators of the anabolic effects of PTH on bone metabolism.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (August 1, 1995): No description
Advertisement
Advertisement